Multiple Sclerosis, Relapsing-Remitting

The disease involves acute episodes of demyelination in the central nervous system. These episodes can occur at multiple sites, including the optic nerves, spinal cord, brain stem, and cerebellum, and are associated with neurologic dysfunction that may improve partially or completely after relapse. The supplied grounding also indicates that early disease activity may include subclinical processes such as cognitive impairment, brain atrophy, fatigue, and silent progression not fully captured by relapse or MRI lesion activity.

The supplied grounding supports early treatment initiation in multiple sclerosis to help prevent irreversible neurological damage and disability progression. Management is described at the level of drug therapy and disease monitoring, with assessment commonly based on relapse rates and MRI lesion activity. The literature also emphasizes treatment and monitoring aimed at detecting and addressing ongoing disease activity, including subclinical progression.